| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -243,790 | -235,930 | -130,900 | 0 | 0 |
| Net Income Growth | -3.33% | -80.24% | unch | unch | unch |
Neumora Therapeutics Inc (NMRA)
1.1300 x 20 1.1900 x 16
Post-market by (Cboe BZX)
1.1300 -0.0300 (-2.59%) 03/21/25 [NASDAQ]
1.1300 x 20 1.1900 x 16
Post-market 1.1300 unch (unch) 16:22 ET
for Fri, Mar 21st, 2025
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass.
Fiscal Year End Date: 12/31